{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:50:02Z","timestamp":1792065002014,"version":"4.4.0"},"reference-count":38,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,9,18]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/bcr-2026-272045","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:00:19Z","timestamp":1792062019000},"page":"e272045","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Approach to management of a severe steroid-refractory immune checkpoint inhibitor-induced hepatitis"],"prefix":"10.1136","volume":"19","author":[{"given":"Steven David","family":"King","sequence":"first","affiliation":[{"name":"Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Hammoud","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young Karen","family":"Choi","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Hepatobiliary Pathology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Haykal","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2026101504001215000_19.10.e272045.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4"},{"key":"2026101504001215000_19.10.e272045.2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.868695","article-title":"The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026101504001215000_19.10.e272045.3","doi-asserted-by":"crossref","unstructured":"Meng L , Wu H , Wu J , et al . Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis 2024;15. doi:10.1038\/s41419-023-06389-5","DOI":"10.1038\/s41419-023-06389-5"},{"key":"2026101504001215000_19.10.e272045.4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.26641","article-title":"Long-Term Survival in Patients With Advanced Melanoma","volume":"7","author":"van Not","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026101504001215000_19.10.e272045.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"2026101504001215000_19.10.e272045.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2026101504001215000_19.10.e272045.7","doi-asserted-by":"crossref","unstructured":"Patrinely JR , McGuigan B , Chandra S , et al . A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology 2021;10. doi:10.1080\/2162402X.2021.1875639","DOI":"10.1080\/2162402X.2021.1875639"},{"key":"2026101504001215000_19.10.e272045.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.03.012"},{"key":"2026101504001215000_19.10.e272045.9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0174"},{"key":"2026101504001215000_19.10.e272045.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00653-1"},{"key":"2026101504001215000_19.10.e272045.11","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000525","article-title":"Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: A systematic review and meta-analysis","volume":"8","author":"Hwang","year":"2024","journal-title":"Hepatol Commun"},{"key":"2026101504001215000_19.10.e272045.12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026101504001215000_19.10.e272045.13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1657332","article-title":"Treatment experience in managing severe immune-mediated hepatotoxicity induced by immune checkpoint inhibitors","volume":"15","author":"Cao","year":"2025","journal-title":"Front Oncol"},{"key":"2026101504001215000_19.10.e272045.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101619","article-title":"The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity","volume":"28","author":"Xing","year":"2023","journal-title":"Transl Oncol"},{"key":"2026101504001215000_19.10.e272045.15","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32120663","article-title":"Steroid-Refractory Cholestatic Immune-Mediated Hepatitis Following Nivolumab Therapy in an Elderly Patient with Metastatic Melanoma: A Rare and Challenging Presentation","volume":"32","author":"Posado-Dominguez","year":"2025","journal-title":"Curr Oncol"},{"key":"2026101504001215000_19.10.e272045.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1679328","article-title":"Case report of immune checkpoint inhibitor induced cholestatic hepatitis, acute renal injury and asymptomatic pancreatic enzyme elevation simultaneously","volume":"16","author":"Jiao","year":"2025","journal-title":"Front Immunol"},{"key":"2026101504001215000_19.10.e272045.17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.063"},{"key":"2026101504001215000_19.10.e272045.18","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jamaoncol.2021.4342","article-title":"Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026101504001215000_19.10.e272045.19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/HEP.0000000000000045","article-title":"Checkpoint inhibitor hepatotoxicity: pathogenesis and management","volume":"79","author":"Cunningham","year":"2024","journal-title":"Hepatology"},{"key":"2026101504001215000_19.10.e272045.20","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4254\/wjh.v14.i7.1269","article-title":"Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach","volume":"14","author":"Bessone","year":"2022","journal-title":"World J Hepatol"},{"key":"2026101504001215000_19.10.e272045.21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1634\/theoncologist.2018-0162","article-title":"Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment","volume":"25","author":"Hsu","year":"2020","journal-title":"Oncologist"},{"key":"2026101504001215000_19.10.e272045.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2026101504001215000_19.10.e272045.23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.625872","article-title":"The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"key":"2026101504001215000_19.10.e272045.24","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073"},{"key":"2026101504001215000_19.10.e272045.25","doi-asserted-by":"crossref","unstructured":"Chen K , He J , Xu J , et al . Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis. Front Oncol 2023;13. doi:10.3389\/fonc.2023.1088741","DOI":"10.3389\/fonc.2023.1088741"},{"key":"2026101504001215000_19.10.e272045.26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17010076","article-title":"Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives","volume":"17","author":"Savino","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026101504001215000_19.10.e272045.27","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001007","article-title":"Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis","volume":"10","author":"Ea","year":"2023","journal-title":"ACG Case Rep J"},{"key":"2026101504001215000_19.10.e272045.28","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001162","article-title":"A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis","volume":"10","author":"Lyles","year":"2023","journal-title":"ACG Case Rep J"},{"key":"2026101504001215000_19.10.e272045.29","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2217\/imt-2023-0085","article-title":"Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature","volume":"15","author":"Ali","year":"2023","journal-title":"Immunotherapy"},{"key":"2026101504001215000_19.10.e272045.30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa\u2019ak","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026101504001215000_19.10.e272045.31","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5908411","article-title":"Plasmapheresis for Pembrolizumab-Induced Hepatitis in a Patient with Squamous Cell Carcinoma and Prior Orthotopic Liver Transplantation","volume":"2022","author":"Al-Nattah","year":"2022","journal-title":"Case Reports Hepatol"},{"key":"2026101504001215000_19.10.e272045.32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1156746","article-title":"Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report","volume":"14","author":"Zarrabi","year":"2023","journal-title":"Front Immunol"},{"key":"2026101504001215000_19.10.e272045.33","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12020539","article-title":"A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma","volume":"12","author":"Gourari","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2026101504001215000_19.10.e272045.34","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?","volume":"2","author":"Katsumoto","year":"2022","journal-title":"Immunother Adv"},{"key":"2026101504001215000_19.10.e272045.35","unstructured":"National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE). 2025."},{"key":"2026101504001215000_19.10.e272045.36","unstructured":"National Cancer Institute . NCI releases updated version of the common terminology criteria for adverse events (CTCAE) reporting in clinical trials. 2026."},{"key":"2026101504001215000_19.10.e272045.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026101504001215000_19.10.e272045.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-272045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:00:24Z","timestamp":1792062024000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-272045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,15]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bcr-2026-272045"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-272045","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}